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Abstract Since bone metastatic breast cancer is an
incurable disease, causing significant morbidity and mor-
tality, an understanding of the underlying molecular
mechanisms would be highly valuable. Here, we describe in
vitro and in vivo evidences for the importance of serine
biosynthesis in the metastasis of breast cancer to bone. We
first characterized the bone metastatic propensity of the
MDA-MB-231(SA) cell line variant as compared to the
parental MDA-MB-231 cells by radiographic and histo-
logical observations in the inoculated mice. Genome-wide
gene expression profiling of this isogenic cell line pair
revealed that all the three genes involved in the L-serine
biosynthesis pathway, phosphoglycerate dehydrogenase
(PHGDH), phosphoserine aminotransferase 1 (PSAT1), and
phosphoserine phosphatase (PSPH) were upregulated in the
highly metastatic variant. This pathway is the primary
endogenous source for L-serine in mammalian tissues.
Consistently, we observed that the proliferation of MDA-
MB-231(SA) cells in serine-free conditions was dependent
on PSAT1 expression. In addition, we observed that L-ser-
ine is essential for the formation of bone resorbing human
osteoclasts and may thus contribute to the vicious cycle of
osteolytic bone metastasis. High expression of PHGDH and
PSAT1 in primary breast cancer was significantly associ-
ated with decreased relapse-free and overall survival of
patients and malignant phenotypic features of breast cancer.
In conclusion, high expression of serine biosynthesis genes
in metastatic breast cancer cells and the stimulating effect of
L-serine on osteoclastogenesis and cancer cell proliferation
indicate a functionally critical role for serine biosynthesis in
bone metastatic breast cancer and thereby an opportunity
for targeted therapeutic interventions.
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Introduction
Metastasis to bone is the most frequent cause of breast
cancer morbidity and mortality. Currently available thera-
pies are able to limit disease progression and alleviate
painful symptoms but bone metastatic cancer remains
incurable. In the metastatic process, tumor cells detach
from the primary site, invade into blood vessels, and
extravasate into the metastatic site. In order to form met-
astatic lesions, tumor cells need to adapt to the bone
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microenvironment and interact with the host cells. The
majority of the skeletal lesions in breast cancer are osteo-
lytic, characterized by enhanced osteoclast activity and
bone destruction. Cancer cells adapt to the bone microen-
vironment and start a vicious cycle causing bone destruc-
tion. Several cancer cell-derived factors, such as
parathyroid hormone-related peptide (PTHrP), have been
shown to contribute to this process [1, 2]. Bone is a rich
source of growth factors, including transforming growth
factor (TGF) a and b, insulin-like growth factors (IGFs),
and fibroblast growth factors (FGFs), which are released as
a consequence of osteoclastic bone resorption and can
stimulate cancer cell survival and production of more
osteolytic factors [3]. However, in order to develop more
effective treatment strategies, a comprehensive under-
standing of the critical molecular mechanisms involved in
the bone metastatic process is needed.
In vivo modeling of bone metastatic breast cancer is
limited by the fact that spontaneous bone metastases are
rare in animals. The MDA-MB-231 breast cancer cell line
is commonly used to model breast cancer bone metastasis
in vivo. This cell line was derived from the pleural effusion
of an estrogen receptor negative, late-stage breast cancer
patient. When MDA-MB-231 cells were inoculated into the
blood circulation of immunodeficient mice by intracardiac
inoculation, osteolytic lesions were formed [4]. MDA-MB-
231 variants with enhanced bone metastatic abilities have
been created, compared, and used for studying molecular
mechanisms of bone metastasis [5, 6]. The MDA-MB-
231(SA) variant has been used in several studies [7, 8] and
is known to be highly bone metastatic. However, com-
parative molecular studies on this variant and the parental
MDA-MB-231 cell line have not been published. Here, we
compared the in vivo bone metastatic properties between
the MDA-MB-231(SA) variant and parental MDA-MB-
231 cells and then used genome-wide gene expression
profiling to identify molecular mechanisms that could
explain the different metastatic properties of the two cell
types.
Materials and methods
Breast cancer cell lines and culture conditions
The parental MDA-MB-231 cancer cell line was obtained
from the American Type Culture Collection (ATCC).
MDA-MB-231(SA) cells were spontaneously derived from
these cells during a long in vitro culture. Both cell types
were maintained in low-glucose DMEM with 10% inacti-
vated fetal bovine serum (FBS), 1% nonessential amino
acids, 100 U/ml penicillin, and 100 lg/ml streptomycin in
an incubator with a humidified atmosphere of 95% air and
5% CO2 at 37C.
Mouse experiments
The animal protocols were approved by the Institutional
Animal Care and Use Committee at the University of
Texas Health Science Center in San Antonio and were in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. 100,000 MDA-
MB-231(SA) or parental MDA-MB-231 cells were inocu-
lated into the left cardiac ventricle of anesthetized (30%
ketamine and 20% xylazine in 0.9% NaCl) 5-week-old
female athymic nude mice (Balb/c nu/nu, Harlan, India-
napolis, IN) (n = 7 mice/cell line) as described previously
[2, 4]. Body weight of the mice was monitored during the
experiment, and the mice were killed when they became
cachectic, or paraplegia was observed. The development of
bone metastases was monitored weekly or bi-weekly by
X-ray radiography. Animals were anaesthetized with
Ketamine–Xylazine cocktail and X-rayed in a prone posi-
tion using a 43855A X-ray system (Faxitron, Lincolnshire,
IL, USA), as described previously [2]. The total area and
number of lesions in hind (left and right tibia and femur)
and fore (left and right humerus) limbs per mouse were
quantified from the images using image analysis software
(Java, Jandel Video Analysis; Jandel Scientific, Corte
Madera, CA, USA). All of the radiographs were evaluated
without knowledge of the treatment groups. Heart, lungs,
spleen, kidneys, liver, and adrenal glands were collected
when killed for histology to determine possible soft tissue
metastasis in addition to the bone metastasis. Tissue sec-
tions (4 lm) were cut and stained with hematoxylin and
eosin (H&E), orange G and phloxine B using standard
protocols.
Genome-wide comparative genomic hybridization
Array-based CGH was performed using Agilent 244K
oligonucleotide microarrays according to the direct method
of the June 2006, version 4 protocol (Agilent Technolo-
gies). Female genomic DNA (Promega) was used as ref-
erence in both hybridizations. Labeling of 3 lg of digested
and purified tumor and reference DNA was performed with
Cy5-dUTP and Cy3-dUTP (Perkin-Elmer), respectively,
according to the protocol. Labeled tumor and reference
samples were pooled and hybridized onto an array. The
arrays were washed and scanned with a laser confocal
scanner (Agilent Technologies). Signal intensities were
extracted using the Feature Extraction software (Agilent
Technologies). CGH Analytics (Agilent Technologies) was
used for initial data analysis and visualization.
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Gene expression profiling
Gene expression levels were measured using the Affyme-
trix GeneChip U133 Plus 2 system (Affymetrix). RNA was
extracted from the parental MDA-MB-231 and MDA-MB-
231(SA) cells using the RNeasy kit (Qiagen) according to
the manufacturer’s instructions. Sample processing and
labeling were performed according to the protocol pro-
vided by Affymetrix. We used 3 lg of total RNA for the
initial cDNA synthesis. Chips were scanned using the
GeneChip Scanner 3000 (Affymetrix). The raw cel files
were processed separately using the R language [9] and the
RMA method implemented in the Bioconductor [10]
package affy [11]. Alternative CDF files mapping Af-
fymetrix probes directly to Ensembl gene IDs were used in
the preprocessing [12]. The microarray data were deposited
in the Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo, accession number GSE20085).
Western blot analyses
Cells were lysed in SDS buffer (containing 30% glycerol,
3% SDS, 3% b-mercaptoethanol, 0.015% bromophenol
blue, and 0.19 M Tris–HCl (pH 6.7)). Lysates were incu-
bated at 95C for 5 min and then loaded into an SDS-
PAGE gel. Separated proteins were transferred to a nitro-
cellulose membrane and immunoblotted using chicken
anti-human PSAT1 antibody (US Biological, Swampscott,
MA, USA), rabbit anti-human PSAT1 antibody (Strategic
Diagnostics Inc., Newark, DE, USA), mouse anti-human
PHGDH antibody (Abnova, Taipei, Taiwan), mouse anti-
b-actin (Sigma) or rat anti-Hsc70 antibody (Stressgen,
Canada). Secondary antibodies: HRP-conjugated donkey
anti-chicken IgY (Jackson ImmunoResearch, West Grove,
PA, USA), IRDye 800-conjugated anti-rabbit IgG (Rock-
land Immunochemicals, Gilbertsville, PA), Alexa Fluor 680
goat anti-mouse IgG (Invitrogen), HRP-conjugated goat
anti-rat IgG (GE Healthcare). The Amersham enhanced
chemiluminescence system (GE Healthcare) was used for
chemiluminescent imaging, and Odyssey Licor device for
fluorescence imaging of proteins.
Quantitative real-time RT-PCR
Total RNA was isolated from cells using RNeasy Mini kit
(Qiagen). Total RNA weighing 300 ng was reverse tran-
scribed using the High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Foster City, CA, USA).
The primers and probes specific for each target gene or the
endogenous control ACTB (b-actin) were designed by the
the ProbeFinder software (Roche Applied Biosciences,
Basel, Switzerland) and are listed in the Online Resource 1
in Electronic supplementary material. The cDNAs were
diluted 1/10, and TaqMan quantitative real-time reverse
transcription PCR (RT-PCR) was performed using the
Applied Biosystems 7900HT instrument. The results were
analyzed using the SDS 2.3 and RQ manager softwares
(Applied Biosystems, Foster City, CA, USA), and the
expression of target mRNA was determined by relative
quantitation using b-actin as an endogenous control.
Generation of shRNA expressing cells
MDA-MB-231(SA) cells were transduced with lentiviral
particles containing an shRNA sequence targeting PSAT1
(Sigma) or a scrambled shRNA sequence not targeting any
human gene (Sigma). Transduction was performed in the
presence of 8 lg/ml hexadimethrine bromide. Transduced
cells were selected with 4 lg/ml puromycin. PSAT1
knockdown was confirmed using quantitative RT-PCR and
Western blotting.
Cell proliferation assay
In order to remove the amino acids, inactivated FBS was
dialyzed against PBS using a dialysis cassette with a
molecular weight cut-off of 2,000 at 4C for 29 h. Cells were
plated in 96-well plates in Minimum Essential Medium
(MEM) (Invitrogen) with 10% dialyzed FBS, 100 U/ml
penicillin, and 100 lg/ml streptomycin. L-serine (Sigma)
was added to the wells at specific concentrations indicated in
the figure legends. Each condition was tested in three rep-
licates. The cells were incubated in a humidified atmosphere
of 95% air and 5% CO2 at 37C. Cell viability was measured
using the CellTiter-Blue Reagent (Promega) according to
the manufacturer’s instructions.
Osteoclast culture
In order to remove the amino acids, FBS (Osteoclast
Medium BulletKit, Lonza) was dialyzed against PBS using
a dialysis cassette with a molecular weight cut-off of 2,000
at 4C for 27 h. A total of 10,000 human osteoclast pre-
cursor cells (Lonza) were seeded onto bovine bone slices
(Nordic Bioscience Diagnostics, Herlev, Denmark) in 96-
well plates and cultured in an incubator with a humidified
atmosphere of 95% air and 5% CO2 at 37C. The culture
conditions for the first 7 days of culture were as follows:
MEM (Invitrogen) with 9% dialyzed FBS and following
supplements from the Osteoclast Medium BulletKit (Lon-
za): 2 mM L-glutamine, 100 U/ml penicillin, 100 lg/ml
streptomycin, 26.6 ng/ml M-CSF, and 53.2 ng/ml soluble
RANKL. The pH of the medium was adjusted to 7.4.
L-serine (Sigma) or O-phospho-DL-serine (Sigma) was
added to the culture wells at specific concentrations indi-
cated in the figure legends for each experiment. After 7
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days of culture, the medium was collected and replaced
with MEM with 9% dialyzed FBS, 2 mM L-glutamine,
100 U/ml penicillin, 100 lg/ml streptomycin, 33 ng/ml
recombinant human M-CSF (R&D Systems), and 66 ng/ml
recombinant human soluble RANKL (PeproTech EC,
London, UK). The pH of the medium was adjusted to 6.9.
L-serine or O-phospho-DL-serine was added to the culture
wells at specific concentrations indicated in the figure
legends for each experiment. Each condition was tested in
at least four replicates. After 11 days of culture, medium
samples were collected. The cells were fixed with 3% PFA
and stained for tartrate-resistant acid phosphatase (TRACP)
using the Acid Phosphatase Leukocyte Kit (Sigma)
according to the manufacturer’s instructions.
Immunoassays
Tartrate-resistant acid phosphatase (TRACP) 5b activity
was measured from the medium samples using a specific
immunoassay (BoneTRAP Assay, Immunodiagnostic
Systems Ltd, Boldon, UK) after 7 days of culture. Bone
resorption was quantified by measuring the concentration
of the degradation products of C-terminal telopeptides of
type I collagen (CTX) in the conditioned medium using the
CrossLaps for Culture ELISA kit (Nordic Bioscience
Diagnostics) after 11 days of culture.
Analysis of gene expression in clinical
breast cancer samples
Association of PHGDH, PSAT1, PSPH, and SLC1A4
expression with time to relapse in the Affymetrix gene
expression studies GSE6532 and GSE12276 (n = 368) and
with overall survival in the Affymetrix gene expression
studies GSE3494 and GSE1456 (n = 393) was assessed by
Kaplan–Meier analysis. Correlation of differential expres-
sion of PHGDH, PSAT1, PSPH, and SLC1A4 with clinical
features was analyzed using a data set of 251 breast tumor
samples hybridized to Affymetrix U133A and U133B
human GeneChips (GSE3494) [13]. U133A and U133B
chips were preprocessed separately using the R language
[9] and the RMA method implemented in the Bioconductor
[10] package affy [11]. Alternative CDF files mapping
Affymetrix probes directly to Ensembl gene ids were used
in preprocessing [12]. Data from U133A and U133B were
combined by calculating the medians of genes appearing
on both array types. TP53 status is based on the classifier
developed by Miller et al. [13]. Breast cancer subtypes
were assigned to samples based on expression data [14].
Ki67, PCNA, and ERBB2 status was likewise estimated
from the expression data itself.
Statistical analysis
The results are reported as mean ± SD. Comparison
between the groups in the in vivo experiment was done
using the one way repeated measures ANOVA (body
weight, lesion area, lesion number) or by a log-rank test
(survival). Statistical significance of the immunoassay and
cell proliferation data were analyzed using an unpaired
Student’s t test. Statistical significance of survival differ-
ences for breast cancer patients was determined by a log-
rank test between the highest quartile and the remaining
three quartiles with respect to the gene expression values.
Results
Bone metastatic activity of MDA-MB-231(SA)
and parental MDA-MB-231 cells in vivo
Owing to the tumor-induced cachexia and paraplegia, all
mice inoculated with MDA-MB-231(SA) cells were killed
on or before day 26 after inoculation (survival 23 ±
4.2 days, mean ± SD). The mean body weight of the
MDA-MB-231(SA) group was significantly smaller already
on day 21 when compared to the parental MDA-MB-231
group (Fig. 1a). The first mouse in the parental MDA-MB-
231 group was killed on day 58, and the mean survival time
in this group was 76.5 ± 19.1 days (mean ± SD) (Fig. 1b).
None of the mice in this group was paraplegic when killed.
Clear osteolytic lesions were observed in six out of seven
mice in the MDA-MB-231(SA) 2 weeks after inoculation
and the lesions were severe when killed (Fig. 1c, Online
Resource 2 in Electronic supplementary material). Histology
revealed no soft tissue metastasis. Only one mouse in the
parental MDA-MB-231 group had a clear osteolytic lesion,
which was visible in X-ray on day 56. However, five mice in
this group had soft tissue tumors according to autopsy and
histology.
Genes involved in L-serine biosynthesis or transport
are overexpressed in the highly bone metastatic
MDA-MB-231(SA) cells
We used array-based comparative genomic hybridization
(CGH) to compare the highly metastatic MDA-MB-
231(SA) variant and the parental cell line. This analysis
showed that the genetic aberrations were highly similar in
the two cell lines (Online Resource 3 in Electronic sup-
plementary material). We then compared the genome-wide
gene expression profiles of the highly metastatic and
parental MDA-MB-231 cells. Only 1.7% (315 genes) of all
genes were over 2.5-fold upregulated and 1.1% (198 genes)
over 2.5-fold downregulated in the highly metastatic
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variant. We used the DAVID functional annotation tool
[15] and WebGestalt gene set analysis toolkit [16] to assess
enrichment of gene ontology (GO) and pathway associa-
tions for the upregulated genes. These analyses indicated
highest enrichment for organic acid metabolic process
(P = 1.3 9 10-6), amino acid and derivative metabolic
process (P = 1.7 9 10-6), amine metabolic process
(P = 2.6 9 10-5), and nitrogen compound biosynthetic
process (P = 5.1 9 10-4) (Online Resource 4 in Elec-
tronic supplementary material). The most significantly
enriched KEGG pathway was Glycine, serine, and threo-
nine metabolism (P = 0.0079) (Online Resource 5 in
Electronic supplementary material). Three genes encoding
the enzymes that catalyze the steps of the phosphorylated
pathway of L-serine biosynthesis (Fig. 2), phosphoglycer-
ate dehydrogenase (PHGDH), phosphoserine aminotrans-
ferase 1 (PSAT1), and phosphoserine phosphatase (PSPH)
are involved in all of the above mentioned enriched GO
categories and in the most significantly enriched pathway,
and upregulated (5.1-, 5.8-, and 2.6-fold, respectively) in
the highly metastatic MDA-MB-231(SA) cells. Further-
more, a transporter for serine, alanine, cysteine, and thre-
onine, SLC1A4 (solute carrier family 1 (glutamate/neutral
amino acid transporter), member 4) was 3.4-fold upregu-
lated in the MDA-MB-231(SA) cells. Overexpression of
PHGDH, PSAT1, PSPH, and SLC1A4 mRNA was con-
firmed by quantitative RT-PCR and overexpression of
PHGDH and PSAT1 at protein level by Western blotting
(Fig. 3).
Expression of genes involved in L-serine biosynthesis
or transport in in vivo selected bone metastatic
MDA-MB-231 variants
Kang et al. [5] profiled gene expression (Affymetrix
U133A) in 12 in vivo selected MDA-MB-231 subpopula-
tions with different bone metastatic abilities and in the
parental MDA-MB-231 cells. We used the data provided
by Kang et al. and compared the expression of PHGDH,
PSAT1, PSPH, and SLC1A4 between the strongly (n = 6)
and weakly (n = 6) metastatic cells. Because the gene
expression data were not publicly available in raw cel
format and therefore not applicable to the normalization
method described above, we used the data at probe set level
Fig. 1 Bone metastatic activity
of MDA-MB-231(SA) and
parental MDA-MB-231 cells in
mice. a Change in body weight
of the mice as a function of time
after inoculation. b Survival of
the mice inoculated with MDA-
MB-231(SA) or parental MDA-
MB-231 cells. c Radiographic
analysis of the osteolytic
lesions. N.D. not determined
because the mice inoculated
with MDA-MB-231(SA) cells
had already been killed before
this time point. * P \ 0.05,
** P \ 0.01, *** P \ 0.001,
significantly different from the
mice inoculated with parental
MDA-MB-231 cells
Fig. 2 Phosphorylated pathway of L-serine biosynthesis
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as given in the supplementary table 1 in Kang et al. [5].
PHGDH expression was significantly higher (P \ 0.001) in
the strongly versus weakly metastatic cells, and the same
was true for SLC1A4, based on two of the four probe sets
(212811_x_at, P \ 0.01; 212810_s_at, P \ 0.05). The
difference in PSAT1 expression between the weakly and
strongly metastatic cells was not significant but PSAT1
expression was the highest in the strongly bone metastatic
subpopulation 1833. PSPH expression did not correlate
with metastatic ability in these MDA-MB-231 subpopula-
tions (Fig. 3c).
Knockdown of serine biosynthesis inhibits
MDA-MB-231(SA) cell proliferation
in serine-free conditions
In order to study whether the phosphorylated pathway of
L-serine biosynthesis is critical for the proliferation of the
MDA-MB-231(SA) cells, we aimed to inhibit one step in
the pathway as efficiently as possible. The best available
shRNA (short hairpin RNA) construct caused 97% reduc-
tion in the PSAT1 mRNA levels when stably expressed in
the MDA-MB-231(SA) cells. PSAT1 silencing was also
confirmed at protein level (Online Resource 6 in Electronic
supplementary material). As a control, we generated MDA-
MB-231(SA) cells stably expressing a scrambled shRNA.
We cultured PSAT1 knockdown and scrambled control
cells as well as parental MDA-MB-231 cells in serine-free
conditions and in varying concentrations of L-serine for
96 h. Cell proliferation rates of all cell types were signif-
icantly lower in the absence of serine than in L-serine
containing medium. However, proliferation of the parental
MDA-MB-231 cells as well as MDA-MB-231(SA) cells
with PSAT1 knockdown was significantly more dependent
on L-serine than that of the MDA-MB-231(SA) scrambled
control cells. 1 lg/ml (9.5 lM) L-serine, which is 1/10–1/42
of the L-serine concentration in the most commonly used cell
culture media and 1/10 of the reported physiological serum
concentration [17], was sufficient to compensate for the
PSAT1 knockdown (Fig. 4).
Effect of L-serine on osteoclastogenesis
Since it was suggested by Ogawa et al. [18] that L-serine is
essential for the osteoclastogenesis of the RAW264 mouse
monocyte/macrophage cell line, we studied whether
L-serine is also needed for the formation of human osteo-
clasts capable of resorbing bone and/or for their bone
resorption activity. We cultured primary human osteoclast
precursors on bone slices in the absence and in two dif-
ferent concentrations of L-serine or phospho-L-serine, and
quantified the extent of osteoclastogenesis, i.e., the amount
of mature osteoclasts, after 7 days of culture by measuring
the activity of an osteoclast specific enzyme, tartrate-
resistant acid phosphatase (TRACP) 5b, in the culture
medium. TRACP 5b activity detected by the immunoassay
has been shown to correlate with the number of osteoclasts
[19]. After 11 days of culture, the cells were also fixed and
Fig. 3 Expression of genes
involved in L-serine
biosynthesis or transport in
MDA-MB-231 cell line
variants. a Expression of
PHGDH, PSAT1, PSPH, and
SLC1A4 mRNA in MDA-MB-
231(SA) as compared to
parental MDA-MB-231 cells
based on Affymetrix profiling
and quantitative RT-PCR
analysis. b PHGDH and PSAT1
protein expression in parental
MDA-MB-231 and MDA-MB-
231(SA) cells determined by
Western blot. c Expression of
PHGDH, PSAT1, PSPH, and
SLC1A4 mRNA in MDA-MB-
231 subpopulations with
different bone metastatic
abilities based on the gene
expression profiling (Affymetrix
U133A) data published by Kang
et al. [5]. * P \ 0.05,
** P \ 0.01, *** P \ 0.001,
significantly different between
the weakly and highly
metastatic groups
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stained with TRACP. In the absence of L-serine and
phospho-L-serine, the TRACP 5b activity was very low
(Fig. 5) and the cells remained mononuclear (data not
shown). Addition of 10 lg/ml (95 lM) L-serine signifi-
cantly increased osteoclastogenesis (P \ 0.01). The effect
of 100 lg/ml L-serine, as well as 100 lg/ml phospho-L-
serine, was more dramatic and significant (P \ 0.001)
(Fig. 5). In addition, we quantified bone resorption by
measuring the concentration of the degradation products of
C-terminal telopeptides of type I collagen (CTX) in the
medium after 11 days of culture. Bone resorption activity
was in line with the number of osteoclasts with the fol-
lowing exceptions: 10 lg/ml L-serine or 100 lg/ml phos-
pho-L-serine in medium during the first 7 days of culture
did not significantly increase bone resorption (Fig. 5).
Expression of genes involved in serine biosynthesis
or transport in clinical breast cancer samples
We used previously published gene expression data on
breast cancer samples to assess clinical significance of
PHGDH, PSAT1, PSPH, and SLC1A4. First, we analyzed
the correlation of PHGDH, PSAT1, PSPH, and SLC1A4
expression to time to relapse in 368 breast cancers and to
overall survival time in 393 breast cancers. Our analysis
demonstrated a significant association between high
PHGDH expression and shorter time to relapse (P \ 0.001)
as well as shorter overall survival time (P = 0.002). Also,
high PSAT1 expression was associated with shorter
relapse-free (P \ 0.001) and overall survival (P = 0.028)
(Fig. 6a, b). High expression of PSPH correlated signifi-
cantly with overall survival (P = 0.003) but not with time
to relapse. SLC1A4 expression did not correlate with time
to relapse or overall survival in these data sets (data not
shown). Second, we looked at whether differential
expression of PHGDH, PSAT1, PSPH, or SLC1A4 corre-
lated with clinically relevant features in a set of 251 breast
cancer samples. High expression of PHGDH and PSAT1
was associated with several features typical of poor out-
come: estrogen and progesterone receptor negative status,
mutated p53, high versus low grade, high expression of the
cell proliferation markers PCNA (proliferating cell nuclear
antigen) and Ki-67, and high ERBB2 expression (Fig. 6c).
A similar but not as strong and significant association was
seen between these clinical parameters and high PSPH
expression. SLC1A4 expression did not correlate with
these parameters (data not shown).
Discussion
We demonstrated the remarkably enhanced bone metastatic
ability of the MDA-MB-231(SA) variant as compared to the
parental MDA-MB-231 cell line. The results from both
array-CGH and gene expression profiling indicated that the
MDA-MB-231(SA) variant was closely related to the
parental cell line suggesting that a limited number of gene
copy number and expression changes were sufficient to
cause a major difference in the metastatic propensity. The
Fig. 4 Proliferation of the MDA-MB-231(SA) and parental MDA-
MB-231 cells in the absence and presence of L-serine and the effect of
PSAT1 knockdown. Cell viability was measured 96 h after cell
plating using the CellTiter-Blue reagent. Results are shown relative to
the cell viability in the presence of 5 lg/ml L-serine. ** P \ 0.01,
*** P \ 0.001
Fig. 5 Effect of L-serine and phospho-L-serine on human osteo-
clastogenesis and bone resorption. Human osteoclast precursors were
cultured in the presence or absence of L-serine or phospho-L-serine.
Medium was changed after 7 days of culture. The activity of an
osteoclast specific enzyme TRACP 5b in the culture medium, as
measured by an immunoassay, indicates the number of differentiated
osteoclasts. Concentration of the degradation products of C-terminal
telopeptides of type I collagen (CTX) was measured to quantify the
bone resorption activity of the differentiated osteoclasts. * P \ 0.05,
** P \ 0.01, *** P \ 0.001, significantly different from the control
(medium without serine and phosphoserine)
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most significantly enriched pathway among the upregulated
genes was L-serine metabolism, and all the three enzymes
involved in the phosphorylated pathway of L-serine bio-
synthesis, PHGDH, PSAT1, and PSPH, were upregulated in
the MDA-MB-231(SA) cells. Especially, there was a very
strong, 648-fold induction of PHGDH expression. There-
fore, this metabolic pathway has a potentially critical func-
tional role in the causation of the metastatic activity of these
cells. This was further supported by the gene expression
profiling data on in vivo selected MDA-MB-231 subpopu-
lations with different bone metastatic abilities: PHGDH
expression was significantly higher in the strongly versus
weakly metastatic cells, and PSAT1 expression was highest
in one of the most highly bone metastatic subpopulations.
As the first step of the phosphorylated pathway of
L-serine biosynthesis, PHGDH catalyzes the oxidation of the
glycolytic intermediate 3-phosphoglycerate to 3-phospho-
hydroxypyruvate. PSAT1 then transaminates 3-phospho-
hydroxypyruvate with glutamate to yield 3-phosphoserine,
and finally, dephosphorylation of 3-phosphoserine by PSPH
produces L-serine. This pathway is the primary source of
L-serine in mammalian tissues [20]. Consistently, our data
indicated that proliferation of MDA-MB-231(SA) cells in
serine-free conditions was strongly inhibited by PSAT1
knockdown. Serine is transported in and out of cells via
amino acid transporters: the Na?-dependent transporters
ASCT1 (SLC1A4) and ASCT2 (SLC1A5) [21, 22], the
system A transporters SA1 (SLC38A1) and SA2 (SLC38A2)
Fig. 6 Expression of PHGDH
and PSAT1 in clinical breast
cancer samples. a Kaplan–
Meier analysis of time to relapse
showing a difference between
patients with high versus low
PHGDH or PSAT1 expression.
b Kaplan–Meier analysis of
survival showing a difference
between patients with high
versus low PHGDH or PSAT1
expression. c PHGDH and
PSAT1 expression in 251 breast
cancer samples in relation to
clinical parameters. ER estrogen
receptor, PgR progesterone
receptor, wt wild type, mut
mutated, Lum luminal,
* P \ 0.05, ** P \ 0.01,
*** P \ 0.001
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[23], and the Na?-independent alanine–serine–cysteine
transporter 1 (Asc-1 (SLC7A10)) [24]. One of these trans-
porters, SLC1A4, was upregulated in the MDA-MB-
231(SA) variant.
Our analysis of gene expression data on breast cancer
patient samples provided evidence for clinical relevance of
the L-serine biosynthesis pathway: high expression of
PHGDH and PSAT1 was associated with shorter time to
relapse and overall survival as well as with several features
typical of poor outcome in breast cancer. This extends
previous observations suggesting that L-serine biosynthesis
is important for cell proliferation [25] and an observation
by Martens et al. [26] who showed that high PSAT1
expression was associated with poor response to tamoxifen
therapy in patients with recurrent breast cancer.
Upon PSAT1 knockdown, proliferation of MDA-MB-
231(SA) cells was severely affected in serine-free medium.
However, even lower than physiological serum concen-
trations of L-serine were able to compensate for the PSAT1
knockdown. L-serine concentrations may be rate-limiting in
the microenvironment of the breast cancer cells in vivo,
such as in the bone marrow or other phases of the meta-
static process, and hence enhanced expression of serine
biosynthesis genes in metastatic cell clones may provide a
selective advantage for cancer progression.
In addition to cell proliferation, our data suggest that
enhanced serine biosynthesis may promote other aspects in
the metastatic cascade. Bone destruction in osteolytic
lesions is mediated by osteoclasts, and breast cancer cells
can stimulate osteoclastogenesis [27]. As suggested by
Ogawa et al. [18], L-serine is essential for the RANKL-
induced osteoclastogenesis of the RAW264 mouse mono-
cyte/macrophage cell line. This cell line is commonly used
as a model for studying osteoclast differentiation but the
resulting multinuclear TRACP positive cells do not resorb
bone. We used primary human osteoclast precursors and
demonstrated that L-serine also stimulated the formation of
human osteoclasts that actively resorbed bone. Enhanced L-
serine production by metastatic breast cancer cells may
thereby contribute to bone destruction. In conclusion,
because L-serine biosynthesis genes are highly expressed in
bone metastatic breast cancer cells and L-serine stimulates
osteoclastogenesis and cancer cell proliferation, interfering
with serine production locally at the bone microenviron-
ment may provide a therapeutic opportunity for metastatic
bone disease.
Acknowledgements This study was supported by the Academy of
Finland Center of Excellence grant (Center of Excellence in Trans-
lational Genome-Scale Biology 2006–2011), TIME (Disseminated
Tumour Cells as Targets for Inhibiting Metastasis of Epithelial
Tumours) project, Drug Discovery Graduate School, NIH grant R01
CA69158 from the National Cancer Institute, and by grants from the
Finnish Cancer Organisations, the Sigrid Juse´lius Foundation, and the
Finnish Cultural Foundation. We thank Barry G. Grubbs and Rami
Ka¨ko¨nen for excellent technical assistance in the mouse studies,
Pharmatest Services Ltd (http://www.pharmatest.fi/) for technical
help and discussions regarding the osteoclast cultures, and John
Patrick Mpindi for help in bioinformatic analyses.
References
1. Vargas SJ, Gillespie MT, Powell GJ et al (1992) Localization of
parathyroid hormone-related protein mRNA expression in breast
cancer and metastatic lesions by in situ hybridization. J Bone
Miner Res 7:971–979
2. Guise TA, Yin JJ, Taylor SD et al (1996) Evidence for a causal
role of parathyroid hormone-related protein in the pathogenesis of
human breast cancer-mediated osteolysis. J Clin Investig
98:1544–1549. doi:10.1172/JCI118947
3. Akhtari M, Mansuri J, Newman KA et al (2008) Biology of breast
cancer bone metastasis. Cancer Biol Ther 7:3–9
4. Yin JJ, Selander K, Chirgwin JM et al (1999) TGF-beta signaling
blockade inhibits PTHrP secretion by breast cancer cells and
bone metastases development. J Clin Investig 103:197–206. doi:
10.1172/JCI3523
5. Kang Y, Siegel PM, Shu W et al (2003) A multigenic pro-
gram mediating breast cancer metastasis to bone. Cancer Cell
3:537–549
6. Yoneda T, Williams PJ, Hiraga T et al (2001) A bone-seeking
clone exhibits different biological properties from the MDA-MB-
231 parental human breast cancer cells and a brain-seeking clone
in vivo and in vitro. J Bone Miner Res 16:1486–1495
7. Bendre MS, Margulies AG, Walser B et al (2005) Tumor-derived
interleukin-8 stimulates osteolysis independent of the receptor
activator of nuclear factor-kappaB ligand pathway. Cancer Res
65:11001–11009. doi:10.1158/0008-5472.CAN-05-2630
8. Kakonen SM, Selander KS, Chirgwin JM et al (2002)
Transforming growth factor-beta stimulates parathyroid hor-
mone-related protein and osteolytic metastases via Smad and
mitogen-activated protein kinase signaling pathways. J Biol
Chem 277:24571–24578. doi:10.1074/jbc.M202561200
9. R Development Core Team (2004) R: a language and environ-
ment for statistical computing. R foundation for statistical com-
puting, Vienna, Austria
10. Gentleman RC, Carey VJ, Bates DM et al (2004) Bioconductor:
open software development for computational biology and bio-
informatics. Genome Biol 5:R80. doi:10.1186/gb-2004-5-10-r80
11. Irizarry RA, Bolstad BM, Collin F et al (2003) Summaries of
Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
12. Dai M, Wang P, Boyd AD et al (2005) Evolving gene/transcript
definitions significantly alter the interpretation of GeneChip data.
Nucleic Acids Res 33:e175. doi:10.1093/nar/gni179
13. Miller LD, Smeds J, George J et al (2005) An expression
signature for p53 status in human breast cancer predicts mutation
status, transcriptional effects, and patient survival. Proc Natl
Acad Sci USA 102:13550–13555. doi:10.1073/pnas.0506230102
14. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation
of breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.
0932692100
15. Dennis G Jr, Sherman BT, Hosack DA et al (2003) DAVID:
database for annotation, visualization, and integrated discovery.
Genome Biol 4:P3
16. Zhang B, Kirov S, Snoddy J (2005) WebGestalt: an integrated
system for exploring gene sets in various biological contexts.
Nucleic Acids Res 33:W741–W748. doi:10.1093/nar/gki475
Breast Cancer Res Treat
123
17. Lewis RM, Glazier J, Greenwood SL et al (2007) L-serine uptake
by human placental microvillous membrane vesicles. Placenta
28:445–452. doi:10.1016/j.placenta.2006.06.014
18. Ogawa T, Ishida-Kitagawa N, Tanaka A et al (2006) A novel role
of L-serine (L-Ser) for the expression of nuclear factor of activated
T cells (NFAT)2 in receptor activator of nuclear factor kappa B
ligand (RANKL)-induced osteoclastogenesis in vitro. J Bone
Miner Metab 24:373–379. doi:10.1007/s00774-006-0705-0
19. Alatalo SL, Halleen JM, Hentunen TA et al (2000) Rapid
screening method for osteoclast differentiation in vitro that
measures tartrate-resistant acid phosphatase 5b activity secreted
into the culture medium. Clin Chem 46:1751–1754
20. Snell K (1984) Enzymes of serine metabolism in normal,
developing and neoplastic rat tissues. Adv Enzyme Regul 22:
325–400
21. Arriza JL, Kavanaugh MP, Fairman WA et al (1993) Cloning and
expression of a human neutral amino acid transporter with
structural similarity to the glutamate transporter gene family. J
Biol Chem 268:15329–15332
22. Broer A, Wagner C, Lang F et al (2000) Neutral amino acid
transporter ASCT2 displays substrate-induced Na? exchange and
a substrate-gated anion conductance. Biochem J 346(Pt 3):705–
710
23. Chaudhry FA, Schmitz D, Reimer RJ et al (2002) Glutamine
uptake by neurons: interaction of protons with system a trans-
porters. J Neurosci 22:62–72
24. Fukasawa Y, Segawa H, Kim JY et al (2000) Identification and
characterization of a Na(?)-independent neutral amino acid
transporter that associates with the 4F2 heavy chain and exhibits
substrate selectivity for small neutral D- and L-amino acids. J Biol
Chem 275:9690–9698
25. de Koning TJ, Snell K, Duran M et al (2003) L-serine in disease
and development. Biochem J 371:653–661. doi:10.1042/BJ20021
785
26. Martens JW, Nimmrich I, Koenig T et al (2005) Association of DNA
methylation of phosphoserine aminotransferase with response to
endocrine therapy in patients with recurrent breast cancer. Cancer
Res 65:4101–4117. doi:10.1158/0008-5472.CAN-05-0064
27. Kozlow W, Guise TA (2005) Breast cancer metastasis to bone:
mechanisms of osteolysis and implications for therapy. J Mam-
mary Gland Biol Neoplasia 10:169–180. doi:10.1007/s10911-
005-5399-8
Breast Cancer Res Treat
123
